Compared with 1.0 μmol/l imatinib for 24 to 72 h, 1.5 μmol/l imatinib resulted in significantly more apoptosis of the CD34+ cells from patients with CML in the megakaryocytic crisis phase in a dose- and time-dependent manner (Fig. 3A). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.